Objective To explore the clinical efficacy of combined use of semeglutide and irbesartan in the treatment of early diabetic nephropathy(DN).Methods A total of 80 patients with early DN admitted to Suining Hospital of Tra-ditional Chinese Medicine from June 2022 to December 2023 were selected as the research objects.According to dif-ferent treatment methods,they were divided into two groups,with 40 cases in each group.The control group was treated with irbesartan,and the observation group was treated with semaglutide combined with irbesartan.The clinical effects,blood glucose indexes[fasting plasma glucose(FPG),2-hour postprandial plasma glucose(2 hPG)and gly-cated hemoglobin A1c(HbA1c)],renal function indexes[serum creatinine(Scr),blood urea nitrogen(BUN)and 24 h urine protein quantification]and inflammatory factor levels[tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and monocyte chemotactic protein 1(MCP-1)]were compared between the two groups.Results The total effective rate of the control group was 82.50%(33/40),which was lower than 97.50%(39/40)of the observation group,and the dif-ference was statistically significant(P＜0.05).The levels of FPG、2 hPG、HbA1c、Scr、BUN、24 h urinary protein、TNF-α、IL-6 and MCP-1 in observation group were lower than those in control group,and the differences were sig-nificant(all P＜0.05).Conclusion In the treatment of early DN,the combination of semaglutide and irbesartan can im-prove the clinical treatment effect,effectively reduce the level of blood glucose and inflammatory factors,and improve renal function.
关键词
司美格鲁肽/厄贝沙坦/早期糖尿病肾病/肾功能指标
Key words
Semeglutide/Irbesartan/Early diabetic nephropathy/Renal function indices
维普
万方数据